Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

Conditions

Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer

Brief summary

This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the body. Stereotactic body radiation therapy delivers fewer, tightly-focused, high doses of radiation therapy to all known sites of cancer in the body while minimizing radiation exposure of surrounding normal tissue.

Detailed description

PRIMARY OBJECTIVES: I. To determine the recommended stereotactic body radiation therapy (SBRT) dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting. SECONDARY OBJECTIVES: I. To estimate rates of \>= grade 3 Common Terminology Criteria for Adverse Events (CTCAE), version (v.) 4.0 adverse events other than a dose-limiting toxicity (DLT) which is possibly, probably, or definitely related to treatment and which occurs within 6 months from the start of SBRT to multiple metastases. II. To estimate the rates of long-term adverse events occurring up to 2 years from the end of SBRT. III. To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness throughout radiation therapy processes, including imaging, simulation, patient immobilization, target and critical structure definition, treatment planning, image guidance and delivery. OUTLINE: Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis. After completion of study treatment, patients are followed up at 35-45 days and then every 3 months for 2 years.

S.J. Chmura, Kathryn Winter, Clifford G. Robinson, Thomas M. Pisansky, Virginia F. Borges et al. (20 authors)

JAMA Oncology2021-04-2298 citations

10.1001/jamaoncol.2021.0687

[ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial

Rachel Glicksman, Ur Metser, John F. Valliant, Peter Chung, Neil Fleshner et al. (19 authors)

BMJ Open2020-04-019 citations

10.1136/bmjopen-2019-035959

Three discipline collaborative radiation therapy (3DCRT) special debate: Equipment development is stifling innovation in radiation oncology

Leonard Kim, Stephanie Markovina, Samantha J. Van Nest, Subarna Eisaman, Lakshmi Santanam et al. (9 authors)

Journal of Applied Clinical Medical Physics2019-05-252 citations

10.1002/acm2.12620

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, Nguyen-Tan FP, Soulières D, Guertin L, Filion E, Christopoulos A, Lambert L, Tehfe M, Ayad T, Charpentier D, Jamal R, Wong P.

2019-01-1436 citations

10.1186/s12885-019-5266-4

Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.

Al-Hallaq HA, Chmura S, Salama JK, Winter KA, Robinson CG, Pisansky TM, Borges V, Lowenstein JR, McNulty S, Galvin JM, Followill DS, Timmerman RD, White JR, Xiao Y, Matuszak MM.

2016-05-2043 citations

10.1016/j.prro.2016.05.004

Interventions

RADIATIONStereotactic Body Radiation Therapy (SBRT)

Undergo SBRT

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Metastatic breast cancer (MBC) OR metastatic non-small cell lung cancer (NSCLC) OR metastatic adenocarcinoma of the prostate; the sites of allowed metastases are: peripheral lung, central lung, mediastinal/cervical lymph node, liver, spinal/paraspinal, osseous, and abdominal-pelvic * NOTE: after the required number of evaluable patients have been accrued for a given dose level, the accrual for that metastatic location will be temporarily suspended while the safety of that dose level is assessed; a patient can only be entered onto the trial if all of their metastatic locations are open to accrual (e.g. if central lung is temporarily suspended for safety assessment and the patient has a central lung metastases, regardless of other metastases, they cannot enroll until the safety of dose to central lung is determined) * Primary tumor site without progression at registration * All metastases not resected must be amenable to SBRT * The patient must meet ONE of the three following criteria: * 3-4 radiographically distinct metastases of any distribution in the allowed anatomical sites OR * 2 radiographically distinct metastases that must be anatomically close (i.e., with less than or equal to 5 cm of normal tissue between them) OR * 3 or 4 distinct metastasis, 2 or 3 to be treated with SBRT and the other (s) having been surgically removed * Evaluation by a radiation oncologist within 45 days prior to study registration * Evaluation by a medical oncologist within 45 days prior to study registration * The following imaging workup to document metastases within 45 days prior to study registration: * Computed tomography (CT) scans of the chest, abdomen and pelvis with radionuclide bone scan OR whole body positron emission tomography (PET)/CT * History/physical examination within 45 days prior to study registration * Zubrod performance status =\< 2 within 45 days prior to study registration * Age \>= 18 years * Absolute neutrophil count (ANC) \>= 500 cells/mm\^3 * Platelets \>= 50,000 /mm\^3 * Hemoglobin \>= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 8.0 g/dl is acceptable) * If liver metastases present, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be \< 3 x upper limit of normal (ULN) * Patient must provide study specific informed consent prior to study entry * For females of child-bearing potential, negative serum/urine pregnancy test within 14 days prior to study registration

Exclusion criteria

* Progression of primary tumor site (breast, prostate, or lung) at time of registration * Metastases with indistinct borders making targeting not feasible * Known brain metastases * Prior palliative radiotherapy to metastases * Metastases located within 3 cm of the previously irradiated structures: * Spinal cord previously irradiated to \> 40 Gy (delivered in =\< 3 Gy/fraction) * Brachial plexus previously irradiated to \> 50 Gy (delivered in =\< 3 Gy/fraction) * Small intestine, large intestine, or stomach previously irradiated to \> 45 Gy (delivered in =\< 3 Gy/fraction) * Brain stem previously irradiated to \> 50 Gy (delivered in =\< 3 Gy/fraction) * Whole lung previously irradiated with prior volume 20 Gy (V20Gy) \> 30% (delivered in =\< 3 Gy/fraction) * Primary tumor irradiated with SBRT * Metastasis irradiated with SBRT * Severe, active co-morbidity, defined as follows: * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration * Transmural myocardial infarction within the last 6 months prior to registration * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration * Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease * Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) 4 count \< 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count \>= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol * End-stage renal disease (i.e., on dialysis or dialysis has been recommended) * Pregnancy or women of childbearing potential not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatment

Design outcomes

Primary

Measure	Time frame	Description
Dose-limiting toxicity (DLT) scored according to the National Cancer Institute (NCI) CTCAE version 4.0 for each of 7 metastatic locations when multiple metastases are treated with SBRT	Within 6 months from the start of treatment; for each of the 7 metastatic locations, analysis occurs after 6 evaluable patients have been followed for a minimum of 6 months from the start of treatment	Adverse events outlined by metastatic location (full detail in protocol) reported as being probably or definitely related to protocol treatment.

Secondary

Measure	Time frame	Description
Rate of long-term adverse events, scored according to the NCI CTCAE v. 4.0	Up to 2 years from end of treatment; analysis occurs after all patients have been potentially followed for 2 years from registration	Adverse events reported as being possibly, probably, or definitely related to protocol treatment.
Rates of >= grade 3 adverse events, scored according to NCI CTCAE v. 4.0	Within 6 months from the start of treatment; analysis occurs after all patients have been followed for a minimum of 6 months from the start of treatment	Adverse events (other than DLTs) reported as being possibly, probably, or definitely related to protocol treatment.

Countries

Canada, Switzerland, United States

Contacts

PRINCIPAL_INVESTIGATORSteven Chmura

NRG Oncology

Outcome results

None listed